WebNov 24, 2024 · Ms. Rachel Mears serves as Partner at Jeito. She also serves as Board Member at Innoskel, HIBio, Neogene and Quell Therapeutics. Over 18 years of experience as an external and in-house counsel and a corporate development executive, with significant experiences in life sciences including licensing, M&A, and regulatory approvals. She is a … WebJEITO’s investment in Noema Pharma is a perfect illustration of our strategy: investing in differentiating and innovative therapies for which the medical… Rachel Mears auf …
Rachel Mears - Neogene Therapeutics
WebNov 29, 2024 · Rachel Mears, Partner at Jeito, and Board Member of Neogene Therapeutics, added: “Over the course of our partnership, Neogene has successfully grown into a world-class cell therapy company ... WebNov 29, 2024 · Rachel Mears, Partner at Jeito Capital, will join Quell’s Board of Directors. Quell is harnessing the full power of Tregs, known as the “master modulators” of immune homeostasis, to create novel cell therapies designed to suppress overactive immune responses, drive long-term tolerance in the local immune environment and promote tissue … pacote prime gaming #6
ESG & Impact (EN) - Jeito
WebMar 7, 2024 · Rachel Mears, Partner at Jeito Capital added: “One of the pillars of our investment strategy is to deploy capital in truly differentiated and innovative therapies … WebRACHEL MEARS Business and legal executive with deep expertise in corporate development, complex transactions, strategy, operations and intellectual property … WebJeito has been founded and is led by a woman, Dr. Rafaèle Tordjman, who is also the Founder & Chairwoman of the association promoting women in healthcare W.I.T.H . … いわびつ コニファー